In yesterday’s newsletter, my colleague Lou Basenese revealed how he spots winning investments — even in the midst of a crisis.
As he explained, “a prepared investor knows how to turn a crisis into a profit opportunity.”
For example, at the beginning of the coronavirus crisis, Lou used this free newsletter to recommend buying Lam Research Corporation (LRCX) and NXP Semiconductors N.V. (NXPI)…
And since then, those two stocks have rallied 75% and 81%, respectively.
But as you’ll learn today, those gains were just the beginning…
How to Profit from Any Trend… and Any Crisis
Lou often uses this free newsletter to share investment recommendations with you.
But as you might know, Lou also runs a premium research service, Micro-Cap Advantage…
For that service, he dives into the most important trends from the worlds of tech and biotech — and every month, he recommends the best way to profit from those trends.
Well, when the coronavirus hit, Lou jumped into action…
He put together a portfolio of stocks that could potentially surge as the crisis raged…
Three “10-Baggers” in 100 Days
Fast-forward 100 days…
And Lou’s already made his subscribers a fortune.
He’s not one to brag, but he’s already delivered not one, not two, but three “10-baggers.”
At this point, he might have the best investment track record I’ve ever seen.
And now, so you can get to know Lou better, I’d like to share a few of the recommendations he made…
Lou’s Recommendation #1: Novavax (NVAX)
This biotech company is one of the front-runners in developing a coronavirus vaccine.
CEPI, a non-profit set up by the Bill & Melinda Gates Foundation, initially awarded it $4 million of funding. But its status as a major contender was confirmed after CEPI awarded it an additional $384 million.
Furthermore, Novavax offers multiple paths to potential profits, as the company is also advancing vaccines for the flu, as well as for other infectious diseases.
On March 27, 2020, Lou recommended buying NVAX at $12.65.
As of yesterday, it was trading at about $108.
That’s almost 1,000% in pure profits…
Enough to turn $5,000 into $50,000.
Lou’s Recommendation #2: Vaxart, Inc. (VXRT)
Vaxart is a clinical-stage biotech company primarily focused on developing vaccines.
Its vaccines are administered by pill rather than by injection.
Pills are easier to administer, transport, and store. That’s why this may represent the best way to achieve the highest vaccination rates as quickly as possible.
Furthermore, Vaxart is already at the head of the pack in terms of getting a potential vaccine into clinics. It plans to start Phase 1 clinical trials in the U.S. shortly.
On March 27, 2020, Lou recommended buying VXRT at $1.70.
As of yesterday, it was trading at about $14.86.
Again, that’s almost 1,000% profits!
Lou’s Recommendation #3: Altimmune, Inc. (ALT)
In February, this biotech company completed the design and synthesis of a novel single-dose intranasal vaccine for COVID-19.
Management expects clinical testing to begin as early as next month.
Furthermore, like Novavax, Altimmune has a pipeline of other high-value drugs, so it offers multiple shots on goal.
On March 27, 2020, Lou recommended buying ALT at $2.70.
As of yesterday, it was trading at about $26.38.
And once again, that’s almost 1,000% profits.
What a Track Record!
Today you learned about Lou’s track record of picking winning investments during a crisis…
And you learned about a few of the most recent recommendations he made, as well as the profits he helped his readers earn.
Tomorrow, Wayne will help you understand the strategy behind Lou’s picks…
In other words, WHY these specific companies exploded in value.
It’s an excellent strategy…
And I think it could help you pick winners in the future — especially as the coronavirus crisis deepens.
Happy Investing
Best Regards,
Founder
Crowdability.com
